These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 6438571)

  • 1. Toxicity of antineoplastic drug combinations in vitrectomy infusion fluid.
    Peyman GA; Barrada A; Greenberg D; Stelmack T; Fiscells R; Yue B
    Ophthalmic Surg; 1984 Oct; 15(10):844-6. PubMed ID: 6438571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin, and thiotepa in primate eyes.
    Barrada A; Peyman GA; Case J; Fishman G; Thomas A; Fiscella R
    Ophthalmic Surg; 1984 Sep; 15(9):767-9. PubMed ID: 6436763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous resistance to vincristine and adriamycin appears at higher frequencies than to vincristine and etoposide in Chinese hamster ovary cells.
    Souès S; Charcosset JY
    Biochem Biophys Res Commun; 1993 Aug; 195(1):65-71. PubMed ID: 8363628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of toxicity of intravitreal antineoplastic drugs.
    Peyman GA; Greenberg D; Fishman GA; Fiscella R; Thomas A
    Ophthalmic Surg; 1984 May; 15(5):411-3. PubMed ID: 6203076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoch-cyclosporin A induces high response rates in relapsed lymphomas.
    Lopez-Picazo JM; Gonzalez Manzano R; Ordoñez Tres JM; Jimenez MM; Calvo JP; Brugarolas A
    Haematologica; 2000 Sep; 85(9):1003-4. PubMed ID: 10980651
    [No Abstract]   [Full Text] [Related]  

  • 7. [Experimental toxicologic and therapeutic studies on the activity of the CMF(cyclophosphamide-methotrexate-5-fluorouracil) scheme versus the VMF(vincristine-methotrexate-5-fluorouracil) scheme].
    Berger MR; Habs M; Schmähl D
    Arch Geschwulstforsch; 1984; 54(4):263-78. PubMed ID: 6548622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro toxicity of taxol based anticancer drug combinations on human hemopoietic progenitors.
    Pannacciulli I; Ballarino P; Castello G; Arboscello E; Botta M; Tredici S; Lerza R
    Anticancer Res; 1999; 19(1A):409-12. PubMed ID: 10226575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy.
    Suzuki M; Sugimoto Y; Tsukahara S; Okochi E; Gottesman MM; Tsuruo T
    Clin Cancer Res; 1997 Jun; 3(6):947-54. PubMed ID: 9815770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of antineoplastic drugs in vitrectomy infusion fluids.
    Barrada A; Peyman GA; Greenberg D; Stelmack T; Fiscella R
    Ophthalmic Surg; 1983 Oct; 14(10):845-7. PubMed ID: 6664662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
    Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
    Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
    J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
    Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.